Patents by Inventor Tyler Maclay

Tyler Maclay has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11607404
    Abstract: This application is directed to inhibitors of RAD51 represented by the following structural formula: in combination with a PARP inhibitor, and methods for their use, such as to treat cancer, autoimmune diseases, immune deficiencies, or neurodegenerative diseases.
    Type: Grant
    Filed: March 25, 2020
    Date of Patent: March 21, 2023
    Assignee: Cyteir Therapeutics, Inc.
    Inventors: Alfredo C. Castro, Melinda Day, Tyler Maclay, Casey Cameron McComas, Kevin Mills, Joseph Vacca
  • Publication number: 20220056022
    Abstract: This application is directed to inhibitors of RAD51 represented by the following structural formula, and methods for their use, such as to treat cancer, autoimmune diseases, immune deficiencies, or neurodegenerative diseases.
    Type: Application
    Filed: June 30, 2021
    Publication date: February 24, 2022
    Inventors: Alfredo C. CASTRO, Casey Cameron MCCOMAS, Joseph VACCA, Tyler MACLAY
  • Patent number: 11084812
    Abstract: This application is directed to inhibitors of RAD51 represented by the following structural formula, and methods for their use, such as to treat cancer, autoimmune diseases, immune deficiencies, or neurodegenerative diseases.
    Type: Grant
    Filed: January 6, 2020
    Date of Patent: August 10, 2021
    Assignee: Cyteir Therapeutics, Inc.
    Inventors: Alfredo C. Castro, Casey Cameron McComas, Joseph Vacca, Tyler Maclay
  • Publication number: 20200397760
    Abstract: This application is directed to inhibitors of RAD51 represented by the following structural formula, and methods for their use, such as to treat pancreatic cancer.
    Type: Application
    Filed: June 22, 2020
    Publication date: December 24, 2020
    Inventors: Alfredo C. CASTRO, Melinda DAY, Tyler MACLAY, Casey Cameron MCCOMAS, Kevin MILLS, Joseph VACCA
  • Publication number: 20200306229
    Abstract: This application is directed to inhibitors of RAD51 represented by the following structural formula: in combination with a PARP inhibitor, and methods for their use, such as to treat cancer, autoimmune diseases, immune deficiencies, or neurodegenerative diseases.
    Type: Application
    Filed: March 25, 2020
    Publication date: October 1, 2020
    Inventors: Alfredo C. CASTRO, Melinda DAY, Tyler MACLAY, Casey Cameron MCCOMAS, Kevin MILLS, Joseph VACCA
  • Publication number: 20200216437
    Abstract: This application is directed to inhibitors of RAD51 represented by the following structural formula, and methods for their use, such as to treat cancer, autoimmune diseases, immune deficiencies, or neurodegenerative diseases.
    Type: Application
    Filed: January 6, 2020
    Publication date: July 9, 2020
    Inventors: Alfredo C. CASTRO, Casey Cameron MCCOMAS, Joseph VACCA, Tyler MACLAY
  • Patent number: 10590122
    Abstract: This application is directed to inhibitors of RAD51 represented by the following structural formula, and methods for their use, such as to treat cancer, autoimmune diseases, immune deficiencies, or neurodegenerative diseases.
    Type: Grant
    Filed: September 11, 2018
    Date of Patent: March 17, 2020
    Assignee: Cyteir Therapeutics, Inc.
    Inventors: Alfredo C. Castro, Casey Cameron McComas, Joseph Vacca, Tyler Maclay
  • Patent number: 10336746
    Abstract: This application is directed to inhibitors of RAD51 represented by the following structural formula, and methods for their use, such as to treat cancer, autoimmune diseases, immune deficiencies, or neurodegenerative diseases.
    Type: Grant
    Filed: December 31, 2018
    Date of Patent: July 2, 2019
    Assignee: Cyteir Therapeutics, Inc.
    Inventors: Alfredo C. Castro, Casey Cameron McComas, Joseph Vacca, Tyler Maclay
  • Publication number: 20190194182
    Abstract: This application is directed to inhibitors of RAD51 represented by the following structural formula, and methods for their use, such as to treat cancer, autoimmune diseases, immune deficiencies, or neurodegenerative diseases.
    Type: Application
    Filed: December 31, 2018
    Publication date: June 27, 2019
    Inventors: Alfredo C. CASTRO, Casey Cameron MCCOMAS, Joseph VACCA, Tyler MACLAY
  • Publication number: 20190077799
    Abstract: This application is directed to inhibitors of RAD51 represented by the following structural formula, and methods for their use, such as to treat cancer, autoimmune diseases, immune deficiencies, or neurodegenerative diseases.
    Type: Application
    Filed: September 11, 2018
    Publication date: March 14, 2019
    Inventors: Alfredo C. Castro, Casey Cameron McComas, Joseph Vacca, Tyler Maclay